MIDLOTHIAN, Va., Aug. 31 /PRNewswire/ -- While previously only available through an exclusive program with SinusPharmacy, PARI Respiratory Equipment, Inc. is embarking on a program to make nasal aerosol delivery systems available nationwide starting September 1, 2006. Pharmacies have been requesting the nasal aerosol delivery system in response to physician and patient requests for prescribed treatments for upper respiratory conditions such as chronic sinusitis, asthma, and severe allergies. Reduced patient costs are expected, while also providing a new revenue stream for compounding pharmacies.
Since many patients, such as chronic sinusitis sufferers or patients that experience reoccurring sinus infections, feel that current therapies are expensive, ineffective, or painful, new therapy options are needed for the more than 35 million sufferers in the United States. Doctors prescribe a variety of therapies, but both physicians and patients have complained that often too much drug is needed to accurately treat the condition systemically through the blood stream (as with pills and intravenous therapies). PARI’s nasal aerosol delivery system, known as PARI SinuStar Aerosol Delivery System provides a targeted, topical delivery of medication through the nose.
By opening the program to all licensed pharmacies in the United States, physicians have the flexibility to work with their trusted, local pharmacy to prescribe medications delivered through a nasal aerosol delivery system at a reduced cost.
PARI SinuStar also provides a new revenue generating program for pharmacies that were previously unable to fill prescriptions calling for nasal aerosol delivery.
About PARI Respiratory Equipment, Inc.
PARI Respiratory Equipment, Inc. (PARI) is a leading developer and manufacturer of fast and efficient aerosol delivery systems for patients with upper and lower airway conditions such as sinusitis, asthma, and COPD. PARI’s mission is to improve the lives of those affected by respiratory diseases and those who care for them by providing innovative and clinically proven solutions.
Inspired by the needs of respiratory patients, PARI produces the world’s leading jet nebulizer (PARI LC Plus), the most advanced electronic inhaler (PARI eFlow), and the only FDA cleared aerosol system for nasal delivery of medications (PARI SinuStar). PARI is headquartered in Starnberg, Germany with a major presence in the United States and offices in Japan, United Kingdom, and China. Online at www.PARI.com
Additional information is available by contacting Ashley Weigand at 804-253-7274 x 711.
Source: PARI Respiratory Equipment, Inc.
